ICMR to advance 1st in-human trials for Zika, flu, blood cancer therapies | Health News
ICMR formalizes MoAs with sponsors for Phase 1 trials of four molecules, partnering with Indian Immunologicals for Zika vaccine, Mynvax for seasonal flu vaccine, Aurigene Oncology for multiple myeloma, and ImmunoACT for CAR-T cell therapy in chronic lymphocytic leukaemia. The trials will be conducted across four Indian institutions, supported by a Central Coordinating Unit at ICMR Headquarters.
Reference News
ICMR formalizes agreements with sponsors for first-in-human phase 1 clinical trials, including research on multiple myeloma, Zika vaccine, seasonal Influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukaemia. This initiative aims to establish India as a leader in pharmaceutical agent clinical development and healthcare innovation.
ICMR signs MoAs with industry and academic partners for First-in-Human Phase 1 clinical trials of four molecules, marking a milestone in affordable healthcare and India's self-sufficiency in clinical development.
ICMR signs MoAs with Aurigene Oncology, Indian Immunologicals, Mynvax, and ImmunoACT for Phase 1 Clinical Trials of multiple myeloma, Zika vaccine, seasonal influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukemia, aiming to enhance India's clinical research capabilities and affordable healthcare innovation.
ICMR formalizes MoAs with sponsors for phase 1 clinical trials of four molecules, aiming to establish India as a leader in pharmaceutical development. Collaborations include research on multiple myeloma, Zika vaccine, seasonal influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukaemia. Dr. Rajiv Bahl emphasizes ICMR's commitment to advancing clinical research through public-private partnerships, aligning with the government's vision of a 'Viksit Bharat'.
ICMR signs MoAs with industry/academic partners for First-in-Human Phase-1 trials of 4 promising molecules: Multiple Myeloma (Aurigene Oncology), Zika Vaccine (Indian Immunologicals), Seasonal Influenza Vaccine (Mynvax), and CAR-T Cell Therapy (ImmunoACT). Aim: establish India as leader in clinical development, ensuring affordable, accessible treatments.
ICMR formalised MoAs with biotech and vaccine firms for First-in-Human Clinical Trials of four molecules, including a Zika vaccine and CAR-T cell therapy for chronic lymphocytic leukemia, aiming to establish India as a leader in pharmaceutical agent development.
India's ICMR formalizes agreements with sponsors to advance first-in-human phase 1 clinical trials for four promising molecules.
ICMR formalizes agreements with sponsors to advance first-in-human phase 1 clinical trials for four molecules, positioning India as a leader in healthcare innovation through strategic public-private partnerships.
ICMR formalised MoAs with sponsors for Phase 1 Clinical Trials, marking entry into First-in-Human trials for four molecules. Collaborations include research on multiple myeloma, Zika vaccine, seasonal Influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukemia. This initiative aims to establish India as a leader in pharmaceutical agent clinical development.
ICMR signs MoAs with industry players for Phase-1 Clinical Trials of four therapeutic candidates, including a multiple myeloma treatment by Aurigene Oncology, a Zika vaccine by Indian Immunologicals, a seasonal influenza vaccine by Mynvax, and CAR-T cell therapy for chronic lymphocytic leukemia by ImmunoACT, to enhance India's clinical research capabilities.
ICMR signs agreements with industry giants to advance first-in-human phase 1 clinical trials for four promising molecules, aiming to establish India as a leader in pharmaceutical agent development and provide accessible healthcare treatments.
ICMR formalizes MoAs with sponsors for Phase 1 trials of four molecules, partnering with Indian Immunologicals for Zika vaccine, Mynvax for seasonal flu vaccine, Aurigene Oncology for multiple myeloma, and ImmunoACT for CAR-T cell therapy in chronic lymphocytic leukaemia. The trials will be conducted across four Indian institutions, supported by a Central Coordinating Unit at ICMR Headquarters.
ICMR formalizes MoAs with sponsors for Phase 1 clinical trials, entering first-in-human trials for four molecules. Collaborations include multiple myeloma research, Zika vaccine development, seasonal influenza vaccine trial, and CAR-T cell therapy study. ICMR aims to establish India as a leader in clinical development.
ICMR formalises agreements with sponsors for first-in-human phase 1 clinical trials, including collaborations on multiple myeloma, Zika vaccine, seasonal Influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukemia, aiming to establish India as a leader in pharmaceutical agent development.